INM 8-K 2026-11-10
InMed Pharmaceuticals Inc. (INM) 8-K dated 2026-11-10 — accession 0001193125-26-455640.
InMed Pharmaceuticals Inc. (INM) is a drug manufacturers - specialty & generic company listed on US.
INM to acquire platform ($490M)
This 8-K covers: Material agreement (Item 1.01), Acquisition or disposition (Item 2.01), Results of operations (Item 2.02), Unregistered share sale (Item 3.02), Change to holders' rights (Item 3.03), Change in control (Item 5.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported INM revenue for 2025-06-30 was $4.9M. Net income was -$8.2M. Revenue was up 7.5% from 2024-06-30 to 2025-06-30. INM currently screens at market cap $5.2M.
Not investment advice. The INM SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “target,” “endeavor,” “p
- Deal
- $490M
Why it matters
- expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “target,” “endeavor,” “p
- Transaction value about $490M